The economic burden of skeletal-related events among elderly men with metastatic prostate cancer

PharmacoEconomics

Volumn 32, Issue 2, 2014, Pages 173-191

  Jayasekera, J ^a   Onukwugha, E ^a   Bikov, K ^a   Mullins, C D ^a   Seal, B ^b   Hussain, A ^c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; BONE NEOPLASMS; COSTS AND COST ANALYSIS; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; PROPENSITY SCORE; PROSTATIC NEOPLASMS; SPINAL CORD COMPRESSION; UNITED STATES;

EID: 84894099296     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0121-y     Document Type: Article

References (28)

1. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manage Care Pharm. 2010;16(9):693-702 pii: 2010(16)9:693-702.
2. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care. 2008;14(5):317-22 pii: 10307.
3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-7. doi: 10.1002/cncr.22991.
4. Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16(1):23-7. doi: 10.1038/pcan.2012.42.
5. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579-84. doi: 10.1093/annonc/mdi122.
6. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: Apopulation-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14(2):177-83. doi: 10.1038/pcan.2011.7.
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s-9s. doi: 10.1158/1078-0432.ccr-06-0931.
8. American Cancer Society. Detailed guide: Prostate cancer what are the key statistics about prostate cancer. Atlanta: ACS; 2013. http://www.cancer.org/ cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics (Accessed 4 April 2013).
9. Gridelli C. The use of bisphosphonates in elderly cancer patients. Oncologist. 2007;12(1):62-71. doi: 10.1634/theoncologist.12-1-62.
10. National Cancer Institute - surveillance, epidemiology and end results. Bethesda: NCI; 2013. http://seer.cancer.gov/registries (Accessed 29 March 2013).
11. Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 2012;97(1):15-20. doi: 10.3324/haematol.2011.051755.
12. U.S. Department of Labor, Bureau of Labor Statistics. Measuring price change for medical care in the CPI. Washington DC: BLS; 2010. http://www.bls.gov/cpi/cpifact4.htm (Accessed 19 Oct 2013).
13. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424. doi: 10.1080/00273171.2011.568786.
14. Bergstralh EJ, Kosanke JL. Computerized matching of controls. Section of Biostatistics Technical Report 56. Rochester: Mayo Foundation; 1995.
15. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33-8. doi: 10.1080/00031305.1985.10479383.
16. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: Apopulation based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162-7.
17. Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: Estimation for the Portuguese National Health System. Value Health. 2011;14(4):499-505. doi: 10.1016/j.jval.2010.11.014.
18. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43(3):226-32.
19. Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004;171(4):1537-42. doi: 10.1097/01.ju.0000116777.94426.60.
20. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419-34.
21. Gray AM, Clarke PM, Wolstenholme JL. Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press Inc.; 2010. p. 157-8.
22. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2012. doi: 10.1097/MLR.0b013e318277eb6f.
23. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006(4):CD006250. doi: 10.1002/14651858.cd006250.
24. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82. doi: 10.1093/jnci/djh141.
25. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-9. doi: 10.1002/cncr.11571.
26. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-71. doi: 10.1200/jco.2008.19. 2146.
27. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. New York: Oxford University Press Inc.; 2007.
28. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall/CRC; 1989.